Metabolic Syndrome

Chronic Fatigue Syndrome

Premature Aging

RiaGev

Prism Research, Inc.

The Safety and Efficacy Study of RiaGev in Healthy Adults

A Randomized, Double-blind, Comparator-controlled, Cross-over Study to Investigate the Safety and Efficacy of RiaGev™ in Healthy Adults

The change in whole blood NAD+ levels from baseline to day 8 when supplemented with RiaGev™ or comparator. The parameter is measured at Day 1, Day 3, Day 5, and Day 8.

The change in serum glucose as assessed by an Oral Glucose Tolerance Test (OGTT) at t=0, 15m, 30, 45m, 60m, 90m and 2h after a 7-day supplementation with either RiaGev™ or comparator. The measure will take place on Day 1 and Day 8

The change in serum insulin as assessed by an Oral Glucose Tolerance Test (OGTT) at t=0, 15m, 30, 45m, 60m, 90m and 2h after a 7-day supplementation with either RiaGev™ or comparator. The measurement take place on Day 1 and Day 8.

The change in serum Glutathione/Glutathione disulfide (GSH/GSSG) ratio after a 7-day supplementation with either RiaGev™ or comparator. The measurement take place on Day 1 and Day 8, before and after exercise.

The change in serum adenosine triphosphate/ adenosine monophosphate (ATP/AMP) ratio after a 7-day supplementation with either RiaGev™ or comparator. The measurement take place on Day 1, Day 3, Day 5, and Day 8.

The change in salivary cortisol after a 7-day supplementation with either RiaGev™ or comparator. The measurement take place on Day 1, 3, 5, and 8.

The change in Checklist Individual Strength (CIS) Questionnaire outcome after a 7-day supplementation with either RiaGev™ or comparator. There are twenty question categorized into four categories, including fatigue, concentration, motivation, and physical activity. The total as well as category score will be reported.

Incidence of pre-emergent and post-emergent adverse events when supplemented

Clinical chemistry parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, creatinine, electrolytes (Na, K, Cl), fasting glucose, and estimated glomerular filtration rate (eGFR). The number of out of norm incidence will be reported.

Hematology parameters including white blood cell (WBC) count with differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils), red blood cell (RBC) count, hemoglobin, hematocrit, platelet count, RBC indices (mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), The number of out of norm incidence will be reported

Vital signs including blood pressure (BP) and heart rate (HR) are going to be measured. Out of norm incidence will be reported.

Bioenergy Life Science, Inc.

KGK Science Inc.

University of Washington

randomized, double-blind, comparator-controlled, cross-over

2 week supplementation with a low nucleotide mycoprotein drink, with added dextrose

2 week supplementation with a high nucleotide mycoprotein drink, with added dextrose

2 week supplementation with a high nucleotide mycoprotein drink, with added ribose

Healthy

2 week, twice daily, supplementation with a nucleotide-depleted mycoprotein drink, with added dextrose

Low nucleotide

2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added dextrose

High nucleotide

2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added ribose

High nucletide + Ribose

University of Exeter - St Luke's Campus

Dietary Nucleotides and Ribose on Muscle Fuel Utilisation

The Effect of Dietary Nucleotides and Ribose on Muscle Fuel Utilisation and Exercise Performance

University of Exeter

Patients with oesophagogastric, hepatobiliary, and colorectal cancer for resectional surgery

Patients undergoing abdominal operation for non-inflammatory, non-cancer conditions

Rectus Muscle Quadriceps Femoris Muscle Tumour Subcutaneous fat Intra-abdominal fat Blood Urine

Cachexia

Royal Infirmary of Edinburgh

Muscle Wasting in Cancer (MWIC)

Biochemical and Functional Biomarkers of Cachexia in Cancer Patients

CT measured muscularity performed on preoperative CT scans using validated software

The soluble protein content of Rectus muscle, as measured by the bicinchoninic acid assay (BCA) method.

Time between operative intervention and patient death as recorded in clinical record

Height and weight will be measured and combined to report BMI in kg/m^2

Gait speed will be measured over a defined distance to produce a gait speed in metres per second

Quality of life will be measured using the "QLQ-C30" questionnaire

Anonymised individual participant data (IPD), including phenotypic data but not including patient identifiable data will be shared with other researchers in collaboration with our research group. Interested parties may contact the lead researcher with data requests.

University of Edinburgh

NHS Lothian

Novartis

825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle.
Patients will be seen on a weekly basis during the time they are on active treatment and will be treated until disease progression.

Gemcitabine: 1000mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle.
Patients will be seen on a weekly basis during the time they are on active treatment and will be treated until disease progression.

Pancreatic Acinar Carcinoma

Pancreatic Neoplasms

825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

Acelarin

1000 mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

Gemcitabine

Cancer Research UK Liverpool Cancer Trials Unit

Acelarin First Line Randomised Pancreatic Study

A Phase III, Open Label, Multicentre Randomised Clinical Study Comparing Acelarin (NUC-1031) With Gemcitabine in Patients With Metastatic Pancreatic Carcinoma

To validate candidate predictive biomarkers, baseline patient samples will be analysed by Luminex technology. Paraffin embedded formalin fixed pancreatic cancer biopsy tissue samples will be used for analysis of candidate predictive biomarkers. Transcripts that will be assayed with RNAScope and scored for staining are: hENT1; CDA, dCK; RRM1 & RRM2. RNAscope will be used to detect mRNA expression by using a site directed probe, to a particular sequence in the gene of interest, which is then amplified and stained. This enables quantification of the mRNA expression and allows subsequent survival analysis.

The Clatterbridge Cancer Centre NHS Foundation Trust

Cancer Research UK

University of Liverpool

Fibromyalgia

D-Ribose Powder

Placebo Powder

Superior Research, LLC

Avail Clinical Research

Renstar Medical Research

University of Kentucky

Columbia Medical Practice

The Center for Rheumatology and Bone Research

Peters Medical Research

Wake Research Associates, LLC

Altoona Center for Clinical Research

D-Ribose for Fatigue in Subjects With Fibromyalgia

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of D-Ribose in Subjects With Fibromyalgia

RiboCor, Inc.

Ribose

Enzymatic Therapy

Treatment of Chronic Fatigue Syndrome and Fibromyalgia With D-ribose- a Multicenter Study

The assessed symptoms were energy, sleep, cognitive function, pain(inverse score) and overall sense of well being. Patients were asked to rate each of the 5 symptoms on a 1 to 7 scale

subjects and health practitioners were asked to report any side effects

Jacob Teitelbaum MD

Kona Research Center

Integrative Therapeutics, Inc.

Fatigue

A 6 gm/day (3 gm/bid) dose of D-ribose in water. Each subject will consume oral D-ribose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.

D-ribose

A 6 gm/day (3 gm/bid) dose of dextrose in water. Each subject will consume oral dextrose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.

ribose/fatigue